Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Particip… (NCT07271186) | Clinical Trial Compass
RecruitingPhase 2
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
United States270 participantsStarted 2026-01-09
Plain-language summary
This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.
The aim of the study is to see how safe and effective the study drugs are.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
. Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
. eGFR 30 to 90 mL/min/1.73 m\^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
. Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening
Exclusion criteria
. Known medical history or clinical evidence indicative of non-diabetic renal disease
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is targeting a protein called ANGPTL3 — can you explain what role that protein plays in diabetic kidney disease, and whether there's any early evidence that blocking it might help protect kidney function?
2Since this is a Phase 2 trial, what do we actually know so far about the safety of ANGPTL3 inhibition in people with diabetic kidney disease, and what risks would I need to weigh against potential benefits?
3The trial is measuring changes in something called the Urine Albumin to Creatinine Ratio — can you help me understand what my current UACR looks like, and why that marker matters for tracking my kidney health?
4Are there already approved treatments for diabetic kidney disease — like SGLT2 inhibitors or medications targeting the renin-angiotensin system — that I should consider trying first before looking at an experimental approach like this one?
5This trial is actively recruiting right now, so if I were interested in discussing it further, what would the participation actually look like in terms of visits, monitoring, and how it might fit into my current treatment routine?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Percent change in Urine Albumin to Creatinine Ratio (UACR)